180 related articles for article (PubMed ID: 11404492)
21. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
22. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series.
Brogan BL; Zic JA; Kinney MC; Hu JY; Hamilton KS; Greer JP
J Am Acad Dermatol; 2003 Aug; 49(2):223-8. PubMed ID: 12894069
[TBL] [Abstract][Full Text] [Related]
23. Intralesional rituximab for cutaneous B-cell lymphoma.
Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type.
Fenot M; Quereux G; Brocard A; Renaut JJ; Dreno B
Eur J Dermatol; 2010; 20(6):753-7. PubMed ID: 20956100
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.
Garbea A; Dippel E; Hildenbrand R; Bleyl U; Schadendorf D; Goerdt S
Br J Dermatol; 2002 Jan; 146(1):144-7. PubMed ID: 11841383
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
[TBL] [Abstract][Full Text] [Related]
27. Rituximab therapy of B-cell neoplasms.
Petryk M; Grossbard ML
Clin Lymphoma; 2000 Dec; 1(3):186-94; discussion 195-6. PubMed ID: 11707828
[TBL] [Abstract][Full Text] [Related]
28. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
[TBL] [Abstract][Full Text] [Related]
30. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients.
Bekkenk MW; Vermeer MH; Geerts ML; Noordijk EM; Heule F; van Voorst Vader PC; van Vloten WA; Meijer CJ; Willemze R
J Clin Oncol; 1999 Aug; 17(8):2471-8. PubMed ID: 10561311
[TBL] [Abstract][Full Text] [Related]
31. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
[No Abstract] [Full Text] [Related]
33. Regression of cutaneous intravascular lymphoma with rituximab.
Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
[TBL] [Abstract][Full Text] [Related]
36. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
[TBL] [Abstract][Full Text] [Related]
37. [Cutaneous marginal zone B-cell lymphoma treated with rituximab].
Pedraz J; Delgado Y; Aragüés M; Fraga J; García-Díez A; Fernández-Herrera J
Actas Dermosifiliogr; 2005 Nov; 96(9):593-7. PubMed ID: 16476304
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
39. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
40. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]